SITAXSENTAN, A SELECTIVE ENDOTHELIN-A RECEPTOR ANTAGONIST, IMPROVES EXERCISE CAPACITY IN PULMONARY ARTERIAL HYPERTENSION (PAH) ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD)

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 219S ◽  
Author(s):  
James Seibold ◽  
David Badesch ◽  
Nazzareno Galie ◽  
David Langleben ◽  
Robert Naeije ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Connective Tissue ◽  
Arterial Hypertension ◽  
Receptor Antagonist ◽  
Exercise Capacity ◽  
Connective Tissue Disease ◽  
Endothelin A Receptor ◽  
Pulmonary Arterial ◽  
Endothelin A

scholarly journals Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan

2006 ◽  
Vol 47 (10) ◽  
pp. 2049-2056 ◽  
Author(s):  
Robyn J. Barst ◽  
David Langleben ◽  
David Badesch ◽  
Adaani Frost ◽  
E. Clinton Lawrence ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Antagonist ◽  
Endothelin A Receptor ◽  
Pulmonary Arterial ◽  
Endothelin A

Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension

CHEST Journal ◽  
2002 ◽  
Vol 121 (6) ◽  
pp. 1860-1868 ◽  
Author(s):  
Robyn J. Barst ◽  
Stuart Rich ◽  
Allison Widlitz ◽  
Evelyn M. Horn ◽  
Vallerie McLaughlin ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Receptor Antagonist ◽  
Clinical Efficacy ◽  
Endothelin A Receptor ◽  
Pulmonary Arterial ◽  
Endothelin A
Sign in / Sign up

Export Citation Format

Share Document